Dr. Michael R. Harrison, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 159
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Tulane University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NC license 2011-00521 · WI license 50617
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
- Duke Regional Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 159
- Services billed
- 612
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 429 | 155 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 43 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Cabometyx (cabozantinib s-malate) | 55 |
| Prednisone Other prescribers in Durham, NC | 55 |
| Bicalutamide | 24 |
| Eliquis (apixaban) Other prescribers in Durham, NC | 23 |
| Orgovyx (relugolix) | 23 |
| Lenvima (lenvatinib mesylate) | 23 |
| Nubeqa (darolutamide) | 23 |
| Xtandi (enzalutamide) | 23 |
| Everolimus | 18 |
| Prochlorperazine Maleate Other prescribers in Durham, NC | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 30 payments worth $13,406 in total to this clinician.
| Janssen Biotech, Inc. | $6,694 |
|---|---|
| Avyxa Pharma, LLC | $3,016 |
| Eisai Inc. | $2,544 |
| Exelixis Inc. | $489 |
| Aveo Pharmaceuticals, Inc. | $364 |
| Pfizer Inc. | $182 |
| AstraZeneca Pharmaceuticals LP | $90.11 |
| Novartis Pharmaceuticals Corporation | $26.34 |
| Consulting Fee | $7,829 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $2,000 |
| Travel and Lodging | $1,924 |
| Food and Beverage | $1,653 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Mar 14, 2025 | Consulting Fee ERLEADA; AKEEGA · Oncology | $3,788 |
| Eisai Inc. Oct 1, 2025 | Consulting Fee Lenvima · Oncology | $2,400 |
| Avyxa Pharma, LLC Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,000 |
| Janssen Biotech, Inc. Mar 28, 2025 | Consulting Fee ERLEADA · Oncology | $1,010 |
| Janssen Biotech, Inc. Feb 24, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $747 |
| Avyxa Pharma, LLC Sep 13, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $648 |
| Janssen Biotech, Inc. Apr 4, 2025 | Consulting Fee ERLEADA; AKEEGA · Oncology | $631 |
| Avyxa Pharma, LLC Sep 13, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $181 |
| Janssen Biotech, Inc. Mar 5, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $150 |
| Janssen Biotech, Inc. Mar 5, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $140 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Oct 1, 2025 | Consulting Fee Lenvima · Oncology | $2,400 |
| Avyxa Pharma, LLC Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,000 |
| Avyxa Pharma, LLC Sep 13, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $648 |
| Avyxa Pharma, LLC Sep 13, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $181 |
| Janssen Biotech, Inc. Apr 4, 2025 | Consulting Fee ERLEADA; AKEEGA · Oncology | $631 |
| Janssen Biotech, Inc. Mar 28, 2025 | Consulting Fee ERLEADA · Oncology | $1,010 |
| Janssen Biotech, Inc. Mar 14, 2025 | Consulting Fee ERLEADA; AKEEGA · Oncology | $3,788 |
| Janssen Biotech, Inc. Mar 5, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $150 |
| Janssen Biotech, Inc. Mar 5, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $140 |
| Janssen Biotech, Inc. Mar 5, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX | $32.00 |
| Janssen Biotech, Inc. Mar 5, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX | $26.74 |
| Janssen Biotech, Inc. Feb 24, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $747 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $264,210 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# substudy 03B in Second-Line Metastatic Participants
Merck Sharp & Dohme LLC - A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03A in First Line Metastatic Participants
Merck Sharp & Dohme LLC - Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
AbbVie Inc. · Recruiting · NCT04777994 - A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03C in Participants with Recurrent Disease After Anti-PD-L1 Adjuvant Therapy
Merck Sharp & Dohme LLC - A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Merck Sharp & Dohme LLC - M20-431 - A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors
AbbVie Inc. - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564
Merck Sharp & Dohme LLC - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.